6月4日，中国生物制药盘中下跌3.14%，报4.62港元，成交额1.86亿港元。
消息面上，摩根士丹利近日发布研报，将中国生物制药目标价由8.3港元下调至7.8港元，维持增持评级。该行纳入新引进授权的bepirovirsen，预计自2027年开始贡献收入，同时根据管理层指引移除来自Sinovac LS的股息收入假设，将2026至2028年每股盈利预测分别下调8%、7%及7%。此外，制药板块今日整体走弱，绿叶制药跌12.9%，恒瑞医药跌4.2%，先声药业跌2.24%，行业系统性抛压加剧个股跌幅。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.